NuvaRing, vaginal ring 11.7mg / 2.7mg 1pc — Made in Netherlands — Free Delivery

Brand: NV Organon
Product Code: NuvaRing
Availability: In Stock

$40.36

Add to Cart

Description

Product description

The vaginal ring "NuvaRing®" is used to prevent pregnancy (contraception).

Compound

One ring contains (active ingredients):

etonogestrel - 11.7 mg;

ethinylestradiol - 2.7 mg.

Excipients: ethylene vinyl acetate copolymer (28% vinyl acetate), ethylene vinyl acetate copolymer (9% vinyl acetate), magnesium stearate.

Contraindications

Combined hormonal contraceptives (CHCs) should not be used in the presence of any of the conditions listed below.

The presence or risk of developing venous thromboembolism (VTE).

venous thromboembolism - the presence of VTE now (treated with anticoagulants) or in history (for example, deep vein thrombosis (DVT) or pulmonary embolism (PES);
known acquired or hereditary risk factors for venous thromboembolism such as resistance to activated protein C (including Factor V Leiden), antithrombin III deficiency, protein C deficiency, protein S deficiency;
extensive surgery with prolonged immobilization;
high risk of developing venous thromboembolism due to the presence of multiple risk factors.
The presence or risk of developing arterial thromboembolism (ATE):
arterial thromboembolism - the presence of a history of arterial thromboembolism (eg myocardial infarction) or a prodromal condition (eg angina pectoris);
cerebrovascular disease - a history of stroke - a stroke or a prodromal condition (for example, transient ischemic cerebrovascular accident);
known hereditary or acquired predisposition to the development of arterial thromboembolism, such as hyperhomocysteinemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant);
migraine in history with local neurological symptoms;
high risk of developing arterial thromboembolism due to the presence of multiple risk factors or one serious risk factor:
diabetes mellitus with vascular complications;
severe form of arterial hypertension;
severe form of dyslipoproteinemia;
pancreatitis or pancreatitis in history, which is accompanied by high hypertriglyceridemia;
severe liver disease (until liver function tests return to normal);
the presence of benign or malignant liver tumors at present or in history;
established or suspected hormone-dependent malignant tumors of the genital organs or mammary glands;
vaginal bleeding of unknown etiology;
hypersensitivity to active substances or to any component of the NuvaRing® preparation.

NuvaRing® is contraindicated for use with a hepatitis C combination regimen that includes ombitasvir/paritaprevir/ritonavir with or without dasabuvir.

Mode of application

The woman herself can insert "NuvaRing®" into the vagina. The doctor should inform the woman how to insert and remove NuvaRing®. To introduce the ring, the woman should choose a position that is comfortable for her, for example, stand with one leg raised, sit down or lie down. "NuvaRing®" must be compressed and inserted into the vagina so that the ring fits comfortably. The exact placement of the NuvaRing® preparation in the vagina is not critical for ring contraception.

Since the introduction of the preparation "NuvaRing®" the ring should remain in the vagina permanently for 3 weeks. A woman should constantly check the presence of the ring in the vagina (for example, before and after intercourse).

"NuvaRing®" must be removed after three weeks on the same day of the week when it was introduced. After a week break, a new ring must be inserted (for example, if the ring was inserted on Wednesday at 22:00, it must be removed on Wednesday after three weeks at 22:00; a new ring should be inserted on the next Wednesday). NuvaRing® can be removed by hooking it with your index finger or by holding the ring between your index and middle fingers. The used ring should be placed in a bag (keep out of the reach of children and pets) and disposed of with normal household waste so as to avoid accidental contact of the ring with other people. "NuvaRing®" should not be flushed into the toilet. Discontinuation bleeding usually begins 2-3 days after NuvaRing® is removed and may not end until the day the next ring is inserted.

Application features

pregnant

Pregnancy is a contraindication for the use of NuvaRing®.

It is not recommended to use "NuvaRing®" during breastfeeding until the child is completely weaned from the breast.

Children

The safety and efficacy of the preparation "NuvaRing®" for persons under 18 years of age have not been studied, therefore, it is not used in patients of this age category.

Drivers

Given the pharmacodynamic properties of the NuvaRing® vaginal ring, there is no likelihood of the preparation affecting the reaction rate when driving vehicles or operating other mechanisms.

Overdose

Serious and dangerous complications due to an overdose of hormonal contraceptives have not been reported. In case of an overdose, side effects may occur: nausea, vomiting, in young women - bloody discharge from the vagina. Treatment of overdose is symptomatic, there are no antidotes.

Side effects

The most commonly reported adverse events in studies were headache and vaginal infections and vaginal discharge, each occurring in 5-6% of women.

Storage conditions

Store in the original packaging at a temperature not exceeding 2-8°C, out of the reach of children.

Shelf life - 40 months.

0 reviews

There are no reviews for this product.